<DOC>
	<DOCNO>NCT00004254</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness raltitrexed treat patient malignant mesothelioma surgically remove .</brief_summary>
	<brief_title>Raltitrexed Treating Patients With Malignant Mesothelioma That Can Be Surgically Removed</brief_title>
	<detailed_description>OBJECTIVES : I . Determine therapeutic activity toxicity raltitrexed patient inoperable malignant mesothelioma . II . Determine objective response rate duration response patient treat regimen . OUTLINE : This multicenter study . Within 2 week stag procedure , patient receive raltitrexed IV 15 minute day 1 . Treatment repeat every 3 week maximum 8 course absence disease progression unacceptable toxicity . Patients follow every 6 week disease progression every 8 week thereafter survival . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven inoperable malignant mesothelioma All tumor stage eligible At least 1 target lesion measurable disease least 1 dimension ( 20 cm conventional technique OR 10 cm spiral CT scan ) Outside irradiated field Prior surgery allow evidence disease progression thereafter No sign symptom CNS metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ZUBROD/ECOG/WHO 02 ( palliative measure pleural drainage ) Life expectancy : Not specify Hematopoietic : Hemoglobin least 10.0 g/dL WBC least 4,000/mm3 Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.46 mg/dL Albumin least 3.0 g/dL ALT AST less 2.5 time upper limit normal ( ULN ) ( less 5 time ULN liver involvement ) Renal : Creatinine le 1.69 mg/dL Creatinine clearance least 65 mL/min Other : No malignancy ( include melanoma , hypernephroma , breast carcinoma ) within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception No uncontrolled infection No psychologic , familial , sociologic , geographic condition could interfere compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent anticancer immunotherapy first disease progression Chemotherapy : No prior systemic intracavitary cytotoxic drug No concurrent intrapleural systemic cytotoxic drug Endocrine therapy : No concurrent anticancer hormonal agent ( except corticosteroid ) first disease progression Radiotherapy : See Disease Characteristics Concurrent palliative radiotherapy allow painful lesion , needle tract , surgical scar prevention metastasis along biopsy track At least 4 week since prior radiotherapy No prior radiotherapy sole indicator lesion unless lesion clearly progressive Surgery : See Disease Characteristics Prior pleurodesis allow except cytotoxic drug ( e.g. , bleomycin ) Concurrent pleurodesis noncytotoxic drug allow Other : At least 1 month since prior investigational agent No concurrent anticancer agent first disease progression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>